The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

Arthritis and Rheumatism

Volumn 60, Issue 7, 2009, Pages 1895-1905

  Kremer, Joel M ^a   Bloom, Bradley J ^b   Breedveld, Ferdinand C ^d   Coombs, John H ^b   Fletcher, Mark P ^c   Gruben, David ^c   Krishnaswami, Sriram ^c   Burgos Vargas, Rubén ^e   Wilkinson, Bethanie ^c   Zerbini, Cristiano A F ^f   Zwillich, Samuel H ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

^f HOSPITAL HELIÓPOLIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ADALIMUMAB; CREATININE; ETANERCEPT; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; PLACEBO;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BALANCE DISORDER; BLURRED VISION; BRONCHITIS; CANDIDIASIS; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYSTITIS; DEATH; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROENTERITIS; HEADACHE; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; INFECTION RATE; INFLUENZA; INTESTINE LIPODYSTROPHY; LEUKOPENIA; LIVER DISEASE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SAFETY; SIDE EFFECT; SPONTANEOUS ABORTION; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TINEA PEDIS; TINEA VERSICOLOR; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ARTHRITIS, RHEUMATOID; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; INTERNATIONAL COOPERATION; JANUS KINASES; MALE; MIDDLE AGED; NAUSEA; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 67650093218     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24567     Document Type: Article

References (28)

1. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13 Suppl 9:S237-51.
2. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [published errata appear in N Engl J Med 2001;344:76 and N Engl J Med 2001;344:240]. N Engl J Med 2000;343:1586-93.
3. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
4. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675-81.
5. Van Vollenhoven RF, Carli CC, Bratt J, Klareskog L. Secondary loss of efficacy with TNFα-antagonists: data from the STURE registry [abstract]. Arthritis Rheum 2005;52 Suppl 9:S136.
6. Kawamura M, McVicar DW, Johnston JA, Blake TB, Chen YQ, Lal BK, et al. Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes. Proc Natl Acad Sci U S A 1994;91:6374-8.
7. Verbsky JW, Bach EA, Fang YF, Yang L, Randolph DA, Fields LE. Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells. J Biol Chem 1996;271:13976-80.
8. Verbsky JW, Randolph DA, Shornick LP, Chaplin DD. Nonhematopoietic expression of Janus kinase 3 is required for efficient recruitment of Th2 lymphocytes and eosinophils in OVA-induced airway inflammation. J Immunol 2002;168:2475-82.
9. Nosaka T, van Deursen JM, Tripp RA, Thierfelder WE, Witthuhn BA, McMickle AP, et al. Defective lymphoid development in mice lacking Jak3 [published erratum appears in Science 1996;271:17]. Science 1995;270:800-2.
10. Thomis DC, Gurniak CB, Tivol E, Sharpe AH, Berg LJ. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science 1995;270:794-7.
11. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, et al. Developmental defects of lymphoid cells in Jak3 kinasedeficient mice. Immunity 1995;3:771-82.
12. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8.
13. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
14. Li X, Jesson M, Lee J, Hirsch J, Saabye M, Bonar S, et al. Characterization of a potent inhibitor of JAK kinases, CP-690,550, and inhibition of specific JAK/STAT pathways at efficacious exposures in a rodent model of arthritis. Presented at Inflammation Research Association, 15th International Conference, 2008 Sep 21-24, Chantilly, Virginia.
15. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10:R14.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
19. Toyoda M, Puliyanda DP, Amet N, Baden L, Cam V, Radha R, et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005;80:198-205.
20. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
21. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996;39:34-40.
22. Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001;28:1163-9.
23. Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Bergeron J, et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001;161:2685-92.
24. Lawendy N, Krishnaswami S, Wang R, Gruben D, Cannon C, Swan S, et al. Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol 2009;49:423-9.
25. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al, for the CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
26. Saiki O, Takao R, Naruse Y, Kuhara M, Imai S, Uda H. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. J Rheumatol 2007;34:1997-2004.
27. Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol 2006;33:2440-6.
28. Changelian PS, Flanagan ME, Ball DJ, Kent CR, Magnuson KS, Martin WH, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302:875-8.